Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

MLA

Stefan Schreiber, et al. “Filgotinib as Induction and Maintenance Therapy for Ulcerative Colitis (SELECTION): A Phase 2b/3 Double-Blind, Randomised, Placebo-Controlled Trial.” Lancet (London, England), vol. 397, no. 10292, Dec. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....669c41099b9478f56e61879a35a15e7f&authtype=sso&custid=ns315887.

APA

Stefan Schreiber, Ian L P Beales, Severine Vermeire, R. Besuyen, John McNally, Timothy E Ritter, Rafał Filip, Chia Hsiang Hsueh, Mamoru Watanabe, Chantal Tasset, Radosław Kempiński, Gerhard Rogler, Sally Zhao, Toshifumi Hibi, William J. Sandborn, Rajiv Mehta, Chohee Yun, Xiaopeng Liu, Hyo Jong Kim, … Sandeep Nijhawan. (2020). Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet (London, England), 397(10292).

Chicago

Stefan Schreiber, Ian L P Beales, Severine Vermeire, R. Besuyen, John McNally, Timothy E Ritter, Rafał Filip, et al. 2020. “Filgotinib as Induction and Maintenance Therapy for Ulcerative Colitis (SELECTION): A Phase 2b/3 Double-Blind, Randomised, Placebo-Controlled Trial.” Lancet (London, England) 397 (10292). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....669c41099b9478f56e61879a35a15e7f&authtype=sso&custid=ns315887.